Results 131 to 140 of about 66,412 (266)

The life and legacy of Dr. Carlton G. Smith

Anatomical Sciences Education, EarlyView.
Abstract Carlton George Smith, M.Sc., M.D., Ph.D., R.C.N.V.R. (1905–2003) was a Canadian anatomist and professor at the University of Toronto. He was highly regarded as an outstanding teacher, cutting‐edge neuroscience researcher, and accomplished author. Dr. Smith became a member of the AAA in 1938 and joined the prestigious Cajal Club in 1950.
Mikaela L. Stiver, Anne M. R. Agur
wiley   +1 more source

Frequentist and Bayesian Predictive Inference for the Log-Logistic Distribution Under Progressive Type-II Censoring. [PDF]

Entropy (Basel)
Zhang Z, Gui W.
europepmc   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

In reply: Why selinexor remains a subpar option? [PDF]

Oncologist
Mohyuddin GR, Meirson T.
europepmc   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Efficient Estimation Methods for the QR Distribution with Type-II Censored Data: An Empirical Validation on Lung Cancer Prognosis. [PDF]

Entropy (Basel)
Ramzan Q, Amin M, Alghamdi S, Alharbi R.
europepmc   +1 more source

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

British Journal of Clinical Pharmacology, EarlyView.
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi, Masato Ozaka, Naoki Sasahira, Yasuhiko Sakata, Yuki Kogure, Shinya Tamaki, Atsushi Wada, Yusuke Taki, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Masakazu Yamaguchi, Kenichi Suzuki   +21 more
wiley   +1 more source

Pregnancy identification method as a source of bias in studies of prenatal exposures using real-world data. [PDF]

Am J Epidemiol
Latour CD, Edwards JK, Funk MJ, Suarez EA, Boggess K, Wood ME.   +5 more
europepmc   +1 more source

Pregnancy‐related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis

British Journal of Clinical Pharmacology, EarlyView.
Aim The number of pregnancies among women with cystic fibrosis (wwCF) has steadily increased over the past decade. However, the pharmacokinetics (PK) of elexacaftor–tezacaftor–ivacaftor (ETI) during gestation remains uncharacterized, despite its widespread use in this population.
Paulette Magnas, Naim Bouazza, Frantz Foissac, Saïk Urien, Léo Froelicher‐Bournaud, Gabrielle Lui, Victoria Guillemart, Nicolas Carlier, Jennifer Da Silva, Johanna Fesenbeckh, Reem Kanaan, Isabelle Honoré, Clémence Martin, Jean‐Marc Treluyer, Vassilis Tsatsaris, Pierre‐Régis Burgel, Sihem Benaboud   +16 more
wiley   +1 more source

Regression methods for cost-effectiveness analysis with different censoring times or terminating events for survival time and costs. [PDF]

Biometrics
Liu D, Chen S.
europepmc   +1 more source